Authors

The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet

Why startups and life sciences companies should approach this booming sector with extreme caution.

Empowering Patients as Partners: The Next Frontier for Pharma Companies

Life sciences organizations have an opportunity to move beyond patient-centered care and embrace a model that values lived experience, fosters collaboration, and positions patients as active contributors to research, treatment, and innovation.

The Dark Side: “Serialized, But Not Secure”

AI’s Next Step in Pharma Quality: From Detection to Closed-Loop Prevention

In the final part of his Pharma Commerce video interview, Shawn Opatka, VP and GM, Honeywell Life Sciences, explains that as pharma quality systems evolve, AI is shifting from reactive problem-solving to proactive, closed-loop risk prevention, enhancing operator insight, decision-making, and continuous process improvement.

Revolutionizing Pharma Patient Assistance Programs, KnippeRx Leads the Future of Patient Care

How the Rise in Self-Injectables Is Impacting Pharmaceutical Manufacturing

As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders become more prevalent, self-injectables are here to stay.

Technically Speaking: Quality Documentation is One of the Best Ways to Boost Performance

Why well-organized documentation is critical at every stage of the process.

Addressing the Threat of Prescription Abandonment

As the rising cost of prescription medications in the United States becomes an increasing barrier for millions of people, how can we effectively address and improve patient adherence?

The New Era of Pharma Distribution: Balancing Precision and Scale

Specialty drugs, cell and gene therapies, and GLP-1s are reshaping pharma distribution, forcing 3PLs to build for both precision and scale.

From Infrastructure to Experience: Why Specialty Therapies Are Reshaping How Organizations Think About Patient Support

Specialty therapies now account for more than half of US drug spending. As innovation accelerates, patient support has expanded to include patient services, digital engagement, specialty pharmacy partnerships, reimbursement support, and personalized programs. As treatments become more individualized, patient journeys grow more complex. They require patients to manage treatment schedules, ongoing self-monitoring, caregiver involvement, and multiple transitions while interacting with providers, reimbursement specialists, specialty pharmacies, and clinical educators. The challenge is that patients rarely experience these capabilities one at a time; they experience how those functions come together, or don't, across their journey, which carries meaningful implications for how engagement is designed. Jennifer Wagner, Senior Vice President of Client Solutions at Momentum Life Sciences, examines why the conversation is shifting from building support to designing programs around how patients experience treatment.

How AI Orchestration Is Reinventing Healthcare Supply Chain Resilience

By unifying data, workflows, and decision-making across partners, AI orchestration is enabling healthcare supply chains to move from reactive firefighting to proactive resilience—supporting faster responses, smarter tradeoffs, and more reliable patient care delivery.

Why Trust Is the Biggest Barrier to Supply Chain Transparency

In the final part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, explains how federated intelligence, audit-ready data systems, and a culture of compliance are enabling scalable transparency across decentralized pharmaceutical manufacturing networks.

Every AI Agent Will Eventually Fail: Why Healthcare Needs AI Supervision, Not Hope

AI agents are moving into healthcare faster than most organizations can supervise them. In this conversation, Amy Brown, CEO of Authenticx, argues that every AI agent will eventually fail—and that the real differentiator isn't which company deploys AI first, but which one can see, catch, and correct what its AI is doing before a patient or member is harmed.

Drug Pricing, PBM Reform, and the 2026 Midterms: What You Need to Know

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

From Uncertainty to Opportunity: Navigating IPAY 2028

How the 2028 Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care

Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?

PwC's Philip Sclafani discusses oral GLP-1 cost exposure, oncology drug spend under the medical benefit, and his outlook on PBM reform.

De-Risking Clinical Development: Strategic Multipliers in Global Trials

How Biopharma Companies Can Optimize Field Reimbursement Models

In the final part of her Pharma Commerce video interview, Megan Wetzel, VP, product, access & affordability at CoverMyMeds, shares how the right field reimbursement model structure ensures field teams have the insights and tools they need to overcome coverage barriers and accelerate patient access to therapy.

Pharma Pulse: Regulatory Speed Records

In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive against fraudulent billing.

How Autonomous AI Is Reshaping Biopharma Operations

Biopharma is using agentic AI to move from tools that inform decisions to systems that execute them, reshaping discovery, clinical trials, commercial launch, and regulatory work.

Modernizing GxP Compliance in Life Sciences: The Role of Digital Tools and Validation Expertise

In an era of increasing regulatory complexity, life sciences organizations are modernizing GxP compliance through digital tools like eQMS, cloud platforms, and automated validation, while expert validation services remain essential for aligning these technologies with real-world workflows and inspection readiness.

Changing the PAP Model

The advantages and challenges associated with structuring a patient assistance program as a non-profit foundation.

Specialty Dispensing Insights: A clearer view of oral utilization trends from medically integrated dispensing community practices

Specialty Dispensing Insights delivers practice, clinic, and physician level perspective on oral therapy use within medically integrated dispensing (MID) pharmacies, including dose and days’ supply metrics, ZIP based activity, competitive prescribing, and trends in new patient starts. These insights offer clear visibility into how oral therapies are utilized within MID practices, helping teams understand the unique prescribing dynamics, geographic variation, and competitive activity across real-world community settings.

Beyond the Brand Team: Why Every Employee Needs to Be Part of the Journey

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

Finding the Human Touch in a Wired World

In the final part of her Pharma Commerce video interview, Jen Butler, CCO at Pleio, emphasizes that as digital tools become central to patient support, there is value to balancing technology with empathy.

Greener, Smarter, and Less Expensive: How Pharma Packaging is Evolving

As the sentiment of surveyed dangerous goods experts backs up, updated packaging pursuits can boost efficiency and cut costs—while mitigating the environmental impact.

Measuring What Matters

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

From Aisles to Access: How Grocery-Based Pharmacies are Evolving into Community Health Hubs

Amid the growing crisis of pharmacy deserts, these entities are tapping new avenues in care delivery, including the integration of clinical services, nutrition counseling, and real-time patient education.

The 2026 Forecast Revisited: Dealmaking, Direct-to-Patient and Patient Affordability

Four pharma experts discuss industry trends in M&A, direct-to-patient sales, patient access and commercial strategy at the H1 midyear mark.